"T1: intermediate intensity lacrimal fossa mass"
"T2: usually hyperintense"
"T1 C+: heterogeneous enhancement"
"Histologic examination shows a well-circumscribed but unencapsulated neoplasm. The cells are highlighted by the calponin immunostain, consistent with myoepithelial differentiation. These cells have round to oval nuclei with a uniform vesicular chromatin pattern and small nucleoli. Most of these cells exhibit cytoplasmic and membranous staining for C-kit (CD117). p53 expression is seen in a minority of the nuclei. A significant number of luminal structures contain mucicarmine-positive material. The tumour cells are uniformly negative for GFAP."
"T1: intermediate intensity lacrimal fossa mass"
"T2: usually hyperintense"
"T1 C+: heterogeneous enhancement"
"DWI and ADC: diffusion restriction of the peripherally enhancing component"
"Adenocarcinoma of the lacrimal glands is rare, with few cases reported in the literature since it was first described in 1996 1. Primary adenocarcinoma of the lacrimal gland is extremely rare; only 9 cases have been reported in the literature 1,2. It can be classified into high- and low-grade malignancies. This neoplasm is histologically and immunohistochemically similar to salivary ductal carcinoma 3."
"The tumour is usually treated with complete excision, lymph node dissection, and adjuvant radiotherapy. Because there are few reports of this entity, its clinical behaviour, prognosis and definitive treatment are still unknown 2,4."